Doha, 18 May 2026: Hamad Medical Corporation’s Department of Laboratory Medicine and Pathology (DLMP) has successfully completed of the simultaneous reaccreditation of its laboratories by both the College of American Pathologists (CAP) and the Association for the Advancement of Blood and Biotherapies (AABB).
The coordinated inspections were conducted from 1 to 8 February 2026, followed by the formal award of CAP re-accreditation in March 2026 and AABB re-accreditation in April 2026, confirming full compliance with internationally recognized standards.
"This dual re-accreditation is a testament to the dedication, professionalism, and unwavering commitment of our DLMP teams across all divisions," said Dr. Einas Al-Kuwari, Chairman, Laboratory Medicine& Pathology. "Achieving simultaneous recognition from both CAP and AABB reflects our culture of continuous improvement and our enduring focus on patient safety, laboratory quality, and clinical excellence. I am proud of our staff and thankful for their collaborative spirit in meeting the highest international standards."
This achievement reflects a high level of system-wide coordination, governance and institutional maturity, demonstrating DLMP’s strong alignment and sustained commitment to laboratory quality, patient safety and clinical excellence.
A total of 12 inspectors participated in the combined inspection process (6 CAP and 6 AABB), highlighting the scale, coordination and complexity of the accreditation activities across DLMP laboratories. The CAP lead inspector highlighted both the uniqueness and scale of the achievement, stating that HMC’s quality management system was among the most extensive he had ever seen, while the AABB inspection team confirmed full compliance with international transfusion medicine and biotherapy standards.
Across the DLMP, accreditation readiness was demonstrated through compliance with 16,455 CAP standards and 479 AABB standards, supported by a comprehensive and integrated quality governance framework that includes:
- 16 Ministry of Public Health (MOPH) indicators
- 60 Quality and Patient Safety (QPS) indicators
- 13 International Patient Safety Goals (IPSG) indicators
- 207 sectional indicators
This framework reflects a mature, data-driven approach to quality management, risk mitigation and continuous performance improvement, aligned with globally recognized best practices.
This achievement further reinforces HMC’s position as a regional and international leader in laboratory and transfusion medicine, and its commitment to delivering the highest standards of quality, safety, and patient-centered care.
